New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
-
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
-
Form SC 13D/A Nkarta, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Form SC 13D/A Robinhood Markets, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Lumos Pharma, Inc. (LUMO) Enters Collaboration with Massachusetts General Hospital to Evaluate LUM-201
-
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
-
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
-
Revelle Aesthetics Unveils New Minimally Invasive Procedure for Cellulite Reduction at Premier Aesthetic Plastic Surgery Conference
-
Form 4 Robinhood Markets, Inc. For: May 02 Filed by: New Enterprise Associates 17, L.P.
-
Sentry Raises $90 Million in Series E Funding to Expand and Drive Adoption of Developer-first Application Monitoring
-
AviadoBio to Present Pre-clinical Data on its Gene Therapy Candidate for Frontotemporal Dementia at ASGCT 2022
-
Pionyr Immunotherapeutics Adds Three Leading Oncology Researchers and Drug Developers to Scientific Advisory Board
-
AviadoBio’s Gene Therapy Candidate Receives Orphan Designation from Food and Drug Administration and European Commission in Frontotemporal Dementia
-
AviadoBio’s Gene Therapy Candidate Receives Orphan Designation from Food and Drug Administration and European Commission in Frontotemporal Dementia
-
Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022
-
Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022
-
Slone Partners Places Richard B. Bartram as Chief Financial Officer at MBX Biosciences
-
Form SC 13D/A IMARA Inc. Filed by: New Enterprise Associates 14, L.P.
-
Form SC 13D/A Trevi Therapeutics, Inc. Filed by: New Enterprise Associates 16, L.P.
-
SOSV RELEASES CLIMATE TECH 100 LIST FOR 2022
-
Wheelhouse Spins out of Lyric With $16 Million in Funding Led by Highgate Ventures and NEA to Strengthen Leadership Position in Accommodation & Rental Software
-
VIPC’s Virginia Venture Partners Invests in Humanitru to Enhance Fundraising Efforts Conducted by Nonprofits
-
Glacier Raises $4.5M to Combat Climate Change with AI-Powered Recycling Robots
-
Multi-Camera 3D Vision Company NODAR Secures $12 Million in Funding from NEA
-
New Web3 Learning Platform, Proof of Learn, Offers A New Approach to Accessible, High-Quality Education Across The Globe
-
/C O R R E C T I O N -- Proof of Learn/
-
Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD
-
Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD
-
MBX Biosciences Appoints Richard B. Bartram as Chief Financial Officer
-
VIPC’s Virginia Venture Partners Investment in SCOUT Supports the First In-Space Observation Systems to Safeguard Orbital Infrastructure
-
Trevi Therapeutics (TRVI) Announces $55 Million Private Placement of Common Stock, Warrants
-
Claudia Fan Munce Joins Arteris IP Board of Directors
-
Claudia Fan Munce Joins Arteris IP Board of Directors
-
Trevi Therapeutics Announces $55 Million Private Placement Priced At-the-Market
-
Gwyneth Paltrow, Cameron Diaz-backed Evernow raises $28.5 million
-
MBX Biosciences Appoints Ora Hirsch Pescovitz, M.D., to Board of Directors
-
Runway Growth Capital Announces a Senior Secured Term Loan of $25 Million to Revelle Aesthetics
-
Lumos Pharma to Participate in the Cantor Rare Disease Symposium
-
Lumos Pharma to Participate in the Cantor Rare Disease Symposium
-
HEAVY.AI Introduces New Capabilities that Enable Organizations to Gain Faster Access to Rapidly Growing Data Sets and Deliver Decision-Quality Information
-
Pionyr Immunotherapeutics Presents on Third Myeloid-Directed Therapeutic Program at Keystone Symposium
-
ForAllSecure Raises $21 Million to Secure the World's Software
-
Topia's Spring Release Reveals Industry-First Arrivals, Continued Expansion of Off-The-Shelf Integrations, and Enhanced Employee Experience
-
Former FDA Head Scott Gottlieb, M.D. to Headline Upcoming Artificial Intelligence in Healthcare and Diagnostics Conference
-
Regulus Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Updates
-
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials
-
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials
-
Top Life Science Venture Partners Join Panel At LSI 2022 Medtech Investor Summit
-
SafeBase, Inc. Raises $18 Million Series A Round to Develop Security Trust Centers for Companies
-
Lumos Pharma to Participate in Upcoming Investor Conferences

